Comparison of using the Medido medication dispenser versus care as usual on Quality of life in patients with Parkinson*s disease
Completed
- Conditions
- Movement disordersParkinson's Disease10028037
- Registration Number
- NL-OMON40139
- Lead Sponsor
- Innospense BV
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 126
Inclusion Criteria
- is older than forty years
- has four or more medication intake moments a day
- has given consent to participate in the study
- is diagnosed with Parkinson*s disease
- will be treated at Medisch Spectrum Twente at Enschede or ZiekenhuisGroep Twente at Hengelo or Almelo.
- may receive personal at-home care
Exclusion Criteria
- not capable of completing the questionnaires
- whose medication is administered by other persons, excluding patients with personal at-home care givers
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method <p>Does the use of Medido improve the physical disabilities of Parkinson*s<br /><br>patients compared with the current method of medication distribution to<br /><br>Parkinson*s patients after a follow-up period of 6 months, as measured by the<br /><br>ALDS questionnaire? </p><br>
- Secondary Outcome Measures
Name Time Method <p>1. What is the cost effectiveness ratio expressed in Cost per QALY of the<br /><br>Medido for Parkinson*s patients relative to current treatment for Parkinson*s<br /><br>patients, as measured by the Euroqol 5D (EQ5D)?<br /><br>2. What is the Quality of life in the Medido groep versus regular care group,<br /><br>as measured by the PDQ-39?<br /><br>3. What is the Quality of life for personal care givers for Parkinson*s<br /><br>patients for care givers in the Medido group versus regular care group, as<br /><br>measured by the PDQ carer questionnaire?<br /><br>4. What is the level of physical disability for patients in the Medido group<br /><br>versus regular care group, as measured by the AMC Linear Disability Score<br /><br>(ALDS)?<br /><br>5. What is the patient experience of motor symptoms in the Medido group versus<br /><br>regular care group, as measured by the Visual Analog Scale (VAS)?<br /><br>6. How many times do you have a off-period during the day, as measured by the<br /><br>MDS-UPDRS? </p><br>